# Aerie Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aerie-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Durham, US
- Website: www.aeriepharma.com
- Total disclosed funding: $51M
- Latest round: Series B (Feb 23, 2011)
- Investors on record: 6

## About

Aerie Pharmaceuticals, Inc. is a biotechnology company focused on the development of innovative therapies for the treatment of eye diseases, particularly glaucoma and ocular hypertension.Founded in 2005 and headquartered in Durham, US, Aerie Pharmaceuticals, Inc. specializes in developing therapies aimed at treating serious ocular conditions. The company has undergone significant transitions, including its recent acquisition by Alcon Labs, Inc. for USD 770 million in August 2022. The firm was co-founded by John Fain, who has a background in developing ophthalmic solutions. Aerie has successfully closed 8 deals, with the most recent funding round being Venture Debt, raising USD 125.000 mn on June 22, 2015, from Deerfield Management. The total amount raised by the company stands at USD 67.000 mn.Aerie Pharmaceuticals focuses on creating innovative ophthalmic treatments, primarily targeting glaucoma and ocular hypertension. Its flagship products include Rocklatan®, a combination treatment, and Rhopressa®, both designed to help manage intraocular pressure. The company is also advancing its pipeline with AR-15512, currently in Phase 3 for dry eye disease, catering to a diverse range of clients including healthcare professionals and clinics globally.In 2021, Aerie Pharmaceuticals recorded a revenue of USD 194.134 mn and reported an EBITDA of USD -39.955 mn for the same year. The company generates revenue through direct sales and partnerships with healthcare providers, allowing access to its innovative products and supporting ongoing education for professionals in the field.Aerie Pharmaceuticals aims to expand its product portfolio by launching new therapies in the coming years, particularly focusing on ophthalmic solutions with anticipated releases in the pipeline targeting ocular conditions. The company plans to penetrate additional international markets to increase its reach, with specific goals set for the next few years. The recent funding of USD 125.000 mn will support these initiatives and assist in enhancing research capabilities to expedite the development of new therapies.

## Funding rounds

- Series B, Feb 23, 2011, $41M — Alta Partners, Blackstone Group, Sofinnova Investments, Clarus Ventures, OUP (Osage University Partners), TPG Biotech
- Series A, Oct 3, 2005, $10M — Alta Partners, TPG Biotech

## Investors

- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series A, Series B
- TPG Biotech (https://capitalatlas.ai/funds/tpg-biotech) — Series A, Series B
- Blackstone Group (https://capitalatlas.ai/funds/blackstone-group) — Series B
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series B
- Clarus Ventures (https://capitalatlas.ai/funds/clarus-ventures) — Series B
- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series B